|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003250,
umls-concept:C0003873,
umls-concept:C0008976,
umls-concept:C0025677,
umls-concept:C0027540,
umls-concept:C0030705,
umls-concept:C0086418,
umls-concept:C0087111,
umls-concept:C0521115,
umls-concept:C1122087,
umls-concept:C1521761,
umls-concept:C2003941
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2003-1-15
|
|
pubmed:abstractText |
To evaluate the efficacy and safety of adalimumab (D2E7), a fully human monoclonal tumor necrosis factor alpha antibody, in combination with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) despite treatment with MTX.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antirheumatic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Collagenases,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Precursors,
http://linkedlifedata.com/resource/pubmed/chemical/Matrix Metalloproteinase 1,
http://linkedlifedata.com/resource/pubmed/chemical/Metalloendopeptidases,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/adalimumab,
http://linkedlifedata.com/resource/pubmed/chemical/prostromelysin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0004-3591
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
48
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
35-45
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12528101-Adult,
pubmed-meshheading:12528101-Aged,
pubmed-meshheading:12528101-Antibodies, Monoclonal,
pubmed-meshheading:12528101-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:12528101-Antirheumatic Agents,
pubmed-meshheading:12528101-Arthritis, Rheumatoid,
pubmed-meshheading:12528101-Collagenases,
pubmed-meshheading:12528101-Combined Modality Therapy,
pubmed-meshheading:12528101-Enzyme Precursors,
pubmed-meshheading:12528101-Fatigue,
pubmed-meshheading:12528101-Female,
pubmed-meshheading:12528101-Humans,
pubmed-meshheading:12528101-Male,
pubmed-meshheading:12528101-Matrix Metalloproteinase 1,
pubmed-meshheading:12528101-Metalloendopeptidases,
pubmed-meshheading:12528101-Methotrexate,
pubmed-meshheading:12528101-Middle Aged,
pubmed-meshheading:12528101-Severity of Illness Index,
pubmed-meshheading:12528101-Treatment Outcome,
pubmed-meshheading:12528101-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.
|
|
pubmed:affiliation |
Rheumatology and Immunology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. mweinblatt@partners.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
